The latest treatment options for bladder cancer. Issue 1 (29th October 2018)

• Record Type: Journal Article
• Authors: Crabb, Simon J; Douglas, James
• Is Part Of: British medical bulletin. Volume 128:Issue 1(2018)
• Page Start: 85
• Page End: 95
• Publication Date: 2018-10-29
• Subjects: bladder cancer -- urothelial cancer -- chemotherapy -- immunotherapy -- intra-vesical -- radiotherapy; Medicine -- Periodicals; 610.5
• DOI: 10.1093/bmb/ldy034
• Languages: English
• ISSNs: 0007-1420

Abstract

Abstract: Introduction: Bladder cancer carries a high healthcare burden and a poor prognosis once distant metastatic spread has occurred. Sources of data: We utilised a PubMed/MEDLINE literature search using the terms bladder cancer, chemotherapy, immunotherapy, intra-vesical therapy, surgery and radiotherapy, and current clinical management guidelines (Association of Cancer Physicians, British Association of Urological Surgeons, National Institute for Health and Care Excellence, European Association of Urology). Areas of agreement: Optimal bladder cancer management requires a multi-modal approach incorporating surgery, radiotherapy, chemotherapy and immunotherapy. Areas of controversy: Selection criteria for radical surgery, or radiotherapy as a bladder sparing option, and their relative efficacy, remains poorly defined. Growing points: Palliative immunotherapy has been recently established for advanced bladder cancer after prior chemotherapy. Earlier use is under investigation. Areas timely for developing research: Validated predictive biomarkers, potentially from easily repeatable sites ('liquid biopsies'), will be required to optimise use of molecularly targeted treatment options.